TLE3 as a marker for chemotherapy
View Patent ↗Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
1. A method for selecting a chemotherapy for a lung or ovarian cancer patient comprising steps of:
providing a cancer sample from a lung or ovarian cancer patient;
detecting the presence of expression of TLE3 in the cancer sample; and
selecting a taxane or taxane derivative for chemotherapy of the cancer patient when the TLE3 expression is present.
2. The method of claim 1 , wherein the cancer patient has lung cancer.
3. The method of claim 2 , wherein the step of selecting comprises selecting a taxane for chemotherapy.
4. The method of claim 3 , wherein the taxane is paclitaxel.
5. The method of claim 3 , wherein the taxane is docetaxel.
6. The method of claim 2 , wherein the step of detecting comprises steps of:
providing a negative control sample;
detecting a level of TLE3 expression in the negative control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the negative control sample.
7. The method of claim 2 , wherein the step of detecting comprises steps of:
providing a positive control sample;
detecting a level of TLE3 expression in the positive control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the positive control sample.
8. The method of claim 2 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
9. The method of claim 3 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
10. The method of claim 4 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
11. The method of claim 5 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
12. The method of claim 8 , wherein the interaction partner is an antibody.
13. The method of claim 9 , wherein the interaction partner is an antibody.
14. The method of claim 10 , wherein the interaction partner is an antibody.
15. The method of claim 11 , wherein the interaction partner is an antibody.
16. The method of claim 2 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
17. The method of claim 3 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
18. The method of claim 4 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
19. The method of claim 5 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
20. The method of claim 1 , wherein the cancer patient has ovarian cancer.
21. The method of claim 20 , wherein the step of selecting comprises selecting a taxane for chemotherapy.
22. The method of claim 21 , wherein the taxane is paclitaxel.
23. The method of claim 21 , wherein the taxane is docetaxel.
24. The method of claim 20 , wherein the step of detecting comprises steps of:
providing a negative control sample;
detecting a level of TLE3 expression in the negative control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the negative control sample.
25. The method of claim 20 , wherein the step of detecting comprises steps of:
providing a positive control sample;
detecting a level of TLE3 expression in the positive control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the positive control sample.
26. The method of claim 20 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
27. The method of claim 21 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
28. The method of claim 22 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
29. The method of claim 23 , wherein the step of detecting comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.
30. The method of claim 26 , wherein the interaction partner is an antibody.
31. The method of claim 27 , wherein the interaction partner is an antibody.
32. The method of claim 28 , wherein the interaction partner is an antibody.
33. The method of claim 29 , wherein the interaction partner is an antibody.
34. The method of claim 20 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
35. The method of claim 21 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
36. The method of claim 22 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.
37. The method of claim 23 , wherein the step of detecting comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.